Amgen and Johnson & Johnson will do more to publicize the safety risks of their anemia drugs for cancer patients, under an agreement reached with government regulators. The risk management plan developed with the Food and Drug Administration is the latest government action to target the blockbuster biotech drugs. Amgen...
more »